Lotiglipron
Lotiglipron (PF-07081532), oral small-molecule GLP-1 receptor agonist
Written by Aaron CuhaReviewed Sep 2026
Also known as: PF-07081532
It worked. 901 participants, HbA1c down 1.44 percent, weight down 7.47 percent against 1.84 on placebo, and the trial was stopped early for safety.
Overview
Lotiglipron is the clearest illustration of why an oral GLP-1 pill was harder than it looked, because the problem was never whether it worked.
Pfizer ran a phase 2 dose-ranging study in 901 participants across two cohorts, type 2 diabetes and obesity. In the diabetes cohort HbA1c fell across every dose, by up to 1.44 percent against 0.07 percent on placebo. In the obesity cohort weight fell across every dose, by up to 7.47 percent against 1.84 percent. Those are real numbers from a large, randomised, double-blind, placebo-controlled trial.
The study was terminated early for safety reasons following routine data and monitoring review, and the planned analyses were modified before unblinding. Development did not continue.
One detail worth noticing in the results: most participants randomised to the higher doses never reached their target maintenance dose, and the drug still produced those effects.
Mechanism of action
A small-molecule agonist at the GLP-1 receptor, taken orally. Unlike semaglutide, which is a peptide requiring an absorption enhancer to survive the gut in tablet form, a small molecule can be absorbed conventionally, which is the entire commercial appeal. It binds the receptor at a site distinct from where the native peptide binds, because a molecule small enough to be swallowed cannot reproduce a peptide's large binding interface. Downstream signalling is the same: glucose-dependent insulin secretion, suppressed glucagon, slowed gastric emptying and reduced appetite.
Human evidence
One large randomised phase 2 with clear efficacy in both diabetes and obesity, stopped early for safety before it could complete as designed.
- 901 participants treated, across separate type 2 diabetes and obesity cohorts.
- HbA1c reduced across every dose at week 16, up to 1.44 percent against 0.07 percent on placebo.
- Weight reduced across every dose at week 20, up to 7.47 percent against 1.84 percent on placebo.
- Most participants assigned to higher doses did not reach their target maintenance dose, so these effects were produced at less than the intended exposure.
- Gastrointestinal events dominated and were dose-related, with nausea reaching 60.6 percent at the highest obesity dose against 12.5 percent on placebo.
- The trial was terminated early for safety reasons and the analyses were modified before unblinding, which is what a sponsor does when a signal appears mid-study.
What this does not tell you: An early termination changes what the efficacy numbers mean. They come from a trial that did not run to plan, with analyses revised before unblinding and with many participants under-dosed relative to the design, so they should be read as indicative rather than definitive. The publicly reported reason for stopping has been described as transaminase elevation, and that specific rationale is not stated in the abstract, so this page reports that the trial was terminated for safety without asserting the mechanism. The nausea figures also deserve attention on their own: 60.6 percent at the top dose is a tolerability problem independent of any safety signal.
Reading the research record
Read the oral small-molecule GLP-1 agonists as a group and one thing stands out. Efficacy was not the obstacle. Lotiglipron cut HbA1c by up to 1.44 percent and produced up to 7.47 percent weight loss against 1.84 percent on placebo in 901 participants, and its trial was terminated early for safety. TERN-601 produced statistically significant dose-dependent weight loss at every dose in phase 1 and significant weight loss at 500 mg and above in phase 2, and was discontinued after three participants developed transaminase elevations consistent with potential drug-induced liver injury. Orforglipron reached approval. Two of three credible programmes were stopped by the liver rather than by a lack of effect, which is a class-level consideration: an orally absorbed small molecule reaches the liver first and at the highest concentration it will encounter anywhere. That does not make every oral agent in this class dangerous, and it does mean liver monitoring is a specific and non-theoretical part of the story rather than boilerplate.
The evidence, charted
Fig. 1 · evidence composition
1of 1 citation (100%) is in people
Every citation cited here is Human work; no other study type is cited on this page. This count is of our own citation list and understates any literature larger than the sources we cite.
Fig. 2 · evidence over time
Every citation here was published in 2025.
Too few distinct publication years on this page to plot as a timeline.
Fig. 3 · legal status at a glance
US
Not approved
UK
Approved
AU
Not approved
CA
Not approved
Approved in 1 of 4, prescription route in 0, not approved in 3. A jurisdiction's classification is a regulatory fact, not a verdict on the science; see Legal status below for the full text and any notes.
Key studies & citations
- Human2025
Evaluation of an oral small-molecule glucagon-like peptide-1 receptor agonist, lotiglipron, for type 2 diabetes and obesity: a dose-ranging study
Phase 2, randomised, double-blind, placebo-controlled, dose-ranging. 901 participants treated with at least one dose, 512 in the type 2 diabetes cohort and 389 in the obesity cohort. Terminated early for safety reasons after routine data and monitoring review, with planned analyses modified before unblinding. HbA1c fell across all doses at week 16 (p < 0.0001), by up to 1.44 percent (90% CI minus 1.63 to minus 1.26) against minus 0.07 percent on placebo. Weight fell across all doses at week 20 (p < 0.01), by up to 7.47 percent (90% CI minus 8.50 to minus 6.43) against minus 1.84 percent on placebo. Most participants on higher doses did not reach their target maintenance dose. Nausea ranged from 4 percent on placebo to 28.8 percent at 80 mg in diabetes, and 12.5 percent on placebo to 60.6 percent at 200 mg in obesity.
Diabetes, Obesity and Metabolism
Frequently asked questions
Did lotiglipron work?
Yes, and that is the point of the page. In 901 participants it cut HbA1c by up to 1.44 percent and body weight by up to 7.47 percent against 1.84 percent on placebo, and it did that while most people on the higher doses never reached their target maintenance dose. It was stopped for safety, not for lack of effect.
Why was it stopped?
The published record says the study was terminated early for safety reasons after routine data and monitoring review, with the planned analyses modified before unblinding. The specific safety finding is not stated in that abstract, so this site does not assert it. What can be said is that a second oral small-molecule programme in the same class, TERN-601, was discontinued after transaminase elevations consistent with potential liver injury.
Does this mean oral GLP-1 pills are unsafe?
No. Orforglipron reached approval, so the class is not inherently doomed. It does mean the liver is the specific thing to watch, because an orally absorbed small molecule reaches the liver first and at the highest concentration it will meet anywhere, and two of three credible programmes were stopped by safety rather than by efficacy.